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Granulomatosis with polyangiitis (GPA) is an autoimmune disease affecting mainly small
blood vessels. B-cells are important in the GPA pathogenesis as precursors of autoanti-
body-producing cells but likely also contribute (auto)antibody-independently. This has been
underlined by the effectiveness of B-cell-depletion (with Rituximab) in inducing and main-
taining disease remission. Mycophenolate-mofetil (MMF) and azathioprine (AZA) are immu-
nosuppressive therapies frequently used in GPA-patients. Interestingly, MMF-treated GPA-
patients are more prone to relapses than AZA-treated patients, while little is known about
the influence of these drugs on B-cells. We investigated whether MMF or AZA treatment (or
their active compounds) alters the circulating B-cell subset distribution and has differential
effects on in vitro B-cell proliferation and cytokine production in GPA-patients that might
underlie the different relapse rate. Circulating B-cell subset frequencies were determined in
samples from AZA-treated (n = 13), MMF-treated (n = 12), untreated GPA-patients (n = 19)
and matched HCs (n = 41). To determine the ex vivo effects of the active compounds of
MMF and AZA, MPA and 6-MP respectively, on B-cell proliferation and cytokine production,
PBMCs of untreated GPA-patients (n = 29) and matched HCs (n = 30) were cultured for 3-
days in the presence of CpG-oligodeoxynucleotides (CpG) with MPA or 6-MP. After restimu-
lation (with phorbol myristate acetate, calcium-ionophore), cytokine-positive B-cell frequen-
cies were measured. Finally, to assess the effect of MMF or AZA treatment on in vitro B-cell
proliferation and cytokine production, PBMCs of MMF-treated (n = 18), and AZA-treated
patients (n = 28) and HCs (n = 41) were cultured with CpG. The memory B-cell frequency
was increased in AZA- compared to MMF-treated patients, while no other subset was differ-
ent. The active compounds of MMF and AZA showed in vitro that MPA decreased B-cell
proliferation in GPA-patients and HCs. B-cell proliferation in MMF- and AZA-treated patients
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was not different. Finally, the IL-6+ B-cell frequency was decreased by MPA compared to 6-
MP. No differences in IL-10+, IL-6+ or TNFα+ B-cell proportions or proliferation were found in
MMF- and AZA-treated patients. Our results indicate that MMF could be superior to AZA in
inhibiting B-cell cytokine production in GPA-patients. Future studies should assess the
effects of these immunosuppressive drugs on other immune cells to elucidate mechanisms
underlying the potential differences in relapse rates.
Introduction
Granulomatosis with polyangiitis (GPA) is a systemic autoimmune disease characterized by
inflammation of small- to medium-sized blood vessels. GPA is associated with the presence of
anti-neutrophil cytoplasmic antibodies (ANCA) mainly directed against proteinase 3 [1].
Patients with GPA frequently suffer from severe disease relapses that increase the disease
burden.
Patients suffering from autoimmune diseases such as GPA and systemic lupus erythemato-
sus (SLE) receive induction- and maintenance immunosuppressive therapy to treat active dis-
ease and prevent disease relapses, respectively. Remission maintenance therapy often consists
of mycophenolate mofetil (MMF) or azathioprine (AZA) combined with glucocorticoids. The
active compounds of both MMF and AZA inhibit purine nucleotide synthesis, which is impor-
tant for DNA synthesis and lymphocyte proliferation [2]. The active compound of MMF,
mycophenolic acid (MPA), inhibits the enzyme inosine monophosphate dehydrogenase 2
(IMPDH2), an isotype which is specifically upregulated in activated lymphocytes. The active
compound of AZA, 6-mercaptopurine (6-MP), non-selectively inhibits IMPDH resulting in
inhibition of all activated immune cells [3–5].
B cells play an important role in the GPA pathogenesis as precursors of ANCA-producing
plasma cells. Importantly, B cells also exert antibody (Ab)-independent properties such as anti-
gen presentation [6] and cytokine production [7]. These Ab-independent B cell functions
gained more interest in GPA since rituximab, a CD20+ B cell depleting monoclonal Ab, was
proven effective in inducing and maintaining disease remission [8,9]. Although the ANCA-
producing CD20- plasma cells are not targeted by rituximab, a gradual decrease in serum
ANCA is seen upon B cell depletion by rituximab and induction of remission in GPA patients
[10]. This finding indicates that the sole presence of ANCA in the circulation, in the absence of
CD20+ B cells, does not induce GPA reactivation and seems to underline the importance of
Ab-independent functions of B cells in the GPA pathogenesis [9]. Indeed, we previously dem-
onstrated several alterations in the B cell compartment of GPA patients [11–13]. An altered B
cell subset distribution in GPA patients was found, characterized by increased circulating
naïve and decreased memory B cell and regulatory B cell (Breg) frequencies [11]. Moreover,
Bregs of GPA patients correlated inversely with T helper (Th) 17 cells and showed decreased
suppression of interleukin (IL)-17-producing Th cells compared to HCs [12]. Lastly, we
recently reported that B cells of GPA patients show increased sensitivity of the B cell receptor
signaling pathway compared to HCs [13], possibly making GPA B cells more prone to become
activated.
Although both MMF and AZA are used to maintain disease remission, the only controlled
study in ANCA-associated vasculitis comparing these drugs showed MMF to be less effective
in maintaining disease remission compared to AZA [14]. It has been shown that although
MMF was inferior to cyclophosphamide as induction therapy [15,16], MMF-treated GPA
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patients had a higher relapse rate [16]. This contrasts with treatment outcome in SLE patients
in whom MMF seems to be as or even more effective in remission maintenance compared to
AZA [17]. In SLE, MMF treatment resulted in a decreased proportion of antigen-experienced
B cells (i.e. memory B cells, plasmablasts and plasma cells), reduced serum IgG [18] and dimin-
ished in vitro B cell IgG and IgM production[19,20]. In vitro addition of MPA to a B cell-cul-
ture resulted in decreased B- [18,19] and plasma cell formation [18]. Moreover, in vitro B cell
IL-10 production was dose-dependently inhibited by MPA [19]. Together these findings point
to a predominant effect of MMF on the Ab-producing function of B cells in SLE patients. The
humoral function of B cells is well known to be an important driver of the SLE pathogenesis
[21], whereas this is less clear in GPA. Importantly, little is known about the in vitro effects of
MPA and 6-MP and the influence of MMF and AZA therapy on B cells of GPA patients.
We hypothesized that the difference in relapse rates between MMF- and AZA-treated GPA
patients may be due to drug-related differential effects on B cell subset distribution and/or
function. In the current study we assessed the in vivo and in vitro effects of MMF and AZA on
B cells of GPA patients.
Materials and methods
Study population
In total, 75 proteinase 3 (PR3)-ANCA positive GPA patients in stable disease remission with or
without maintenance immunosuppressive therapy for at least three months were enrolled in
this study. The diagnosis of GPA was based on criteria determined in the Chapel Hill Consensus
Conference and classification criteria of the American College of Rheumatology were met
[22,23]. Remission was defined as absence of clinical disease activity as reflected by a Birming-
ham vasculitis activity score (BVAS) score of zero. All patients had received induction therapy
with cyclophosphamide and corticosteroids, but all treated patients ceased cyclophosphamide
treatment at least three months before sampling and switch to treatment with MMF or AZA.
To determine changes in B cell phenotype between treatment groups and in vitro B cell
cytokine production, MMF- (n = 12) and AZA-treated (n = 13) GPA patients, and age-
matched healthy controls (HCs; n = 22)) were included (Treated Cohort 1; Table 1). To assess
the in vitro effect of the active compounds of MMF (MPA) and AZA (6-MP) on these parame-
ters, we included a second cohort of GPA patients in remission (n = 19), receiving no (n = 18)
Table 1. Characteristics of HCs and GPA patients for each cohort.
Treated Cohort 1 Untreated Cohort 2 Untreated Cohort 3 Treated Cohort 4
HCs GPA HCs GPA HCs GPA GPA
Subjects, n (% male) 22 (45.5) 24 (29.2) 19 (47.4) 19 (42.1) 11 (54.5) 10 (50) 19 (42.1)
Age, mean (range) 59.5 (39–74) 59.6 (33–78) 54.8 (44–71) 54.6 (28–78) 58.5 (25–83) 55.6 (30–71) 55.4 (31–78)
cANCA titer, median (range) 1:40 (0–1:640) 1:40 (0–1:640) 0 (0–1:320) 1:20 (0–1:320)
Creatinine μmol/L, median (range) 81 (65–152) 88 (59–190) 82 (53–155) 89 (52–132)
CRP mg/L, median (range) 4.2 (0.3–40) 2.9 (0.6–19) 2.8 (0.6–8) 2.1 (0–14)
IS therapy at time of sampling, n (%) 25 (100) 1 (5.3) 0 (0) 19 (100)
AZA, n (%) 4 (30.8) 5 (26.3)
AZA + Pred, n (%) 9 (69.2) 10 (47.4)
MMF + Pred, n (%) 11 (100) 5 (100)
Pred, n (%) 1 (5.3)
Dosage AZA mg/day, median (range) 76.9 (25–150) 125 (21.5–200
Dosage MMF mg/day, median (range) 1615.4 (500–3000) 2000 (1000–2000)
https://doi.org/10.1371/journal.pone.0235743.t001
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or only a low dose prednisolone (n = 1) and age- and sex-matched HCs (n = 19; Untreated
Cohort 2; Table 1). To determine the in vitro effect of MPA and 6-MP on B cell proliferation,
we included a third cohort of GPA patients in remission receiving no immunosuppressive
medication (n = 10) and matched HCs (n = 11; Untreated Cohort 3; Table 1). To determine in
vitro B cell proliferation in treated patients, we included a fourth cohort of MMF-treated GPA
patients (n = 5), AZA-treated GPA patients (n = 14), both in remission, and the same matched
HCs as included in Untreated Cohort 3 (Treated Cohort 4; Table 1).
This study was approved by the medical ethics committee of the University Medical Center
Groningen (METc no. 2012/ 151), informed written consent was obtained from all patients
and the study complies with the Declaration of Helsinki.
Flow cytometry analysis of B cell subsets
EDTA venous blood was obtained from patients and HCs and immediately washed twice in
PBS with 1% BSA (wash buffer). Next, 100 μl blood was incubated with anti-human CD19-e-
Fluor450, CD27-APC-eFluor780, CD38-PE-Cy7 (eBioscience, San Diego, CA, USA),
CD24-FITC, IgM-APC, IgD-PE (BD Biosciences, San Jose, CA, USA) or corresponding iso-
type controls for 15 minutes and treated with 10x FACS Lysing solution (BD Biosciences) for
10 minutes. After washing, samples were acquired on a FACS LSR-II flow cytometer (BD Bio-
sciences). At least 200,000 events were measured and plotted using Kaluza v1.5a flow analysis
software (Beckman Coulter, Brea, CA, USA) or FlowJo v10 analysis software (Treestar, Ash-
land, OR, USA). S1A Fig and Fig 1A show representative gating examples.
Fig 1. Memory B cells are increased in AZA-treated GPA patients compared with MMF-treated patients. A.
Representative gating example of the B cell subsets. All gates were set on respective isotype controls. Within CD19+ B
cells, we first gated on CD38hiCD27- transitional B cells, CD38-/dimCD27- naïve B cells, CD38-/dimCD27+ memory B
cells and CD38hiCD27+ plasmablasts using the CD38/CD27 plot. In the CD24/CD38 plot we determined the
CD24hiCD38hi Bregs and in the CD24/CD27 plots we gated on CD24hiCD27+ Bregs. B. The frequencies of B cells and
B cell subsets in MMF- (open diamonds) and AZA-treated (circles) GPA patients. Red lines represent the median
value. �p<0.05.
https://doi.org/10.1371/journal.pone.0235743.g001
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B cell proliferation
Peripheral blood mononuclear cells (PBMCs) were isolated, frozen and thawed as described
before [24]. PBMCs were washed twice in PBS, followed by a 15-minute incubation at 37˚C
with eFl670 (eBioscience). Next, PBMCs were cultured in the presence or absence of 500 ng/
mL CpG (Hycult Biotech, Uden, the Netherlands), with 3 μM MPA or 3 μM 6-MP (Sigma-
Aldrich, St. Louis, MO, USA). After 3 days of culture, samples were washed and stained with
anti-human CD19-eFluor 450, CD22-APC (BioLegend, San Diego, CA, USA) and
CD3-BV786 (BD Biosciences). At least 200.000 cells were acquired and plotted using Kaluza
v1.5a or FlowJo v10. In S2 Fig and Fig 2A representative gating examples are given.
Determination of in vitro B cell cytokine production
To determine the in vitro effects of 6-MP and MPA on B cell cytokine production PBMCs were
cultured at a concentration of 1�106 cells/mL in the presence of 500 ng/mL CpG alone or in
combination with 3 μM MPA or 3 μM 6-MP. After 3 days of culture, PBMCs were restimulated
for 5 hours with 2 mM calcium ionophore (Ca-I) and 50 ng/mL phorbol myristate acetate
(PMA) in the presence of 10 μg/mL brefeldin A (BFA; Sigma-Aldrich). Next, cells were stained
with Zombie Dye NIR (BioLegend) to exclude dead cells. Cells were washed in PBS with 1%
BSA (wash buffer) and stained for 15 minutes with anti-human CD19-eFluor 450, CD22-PE-
Fig 2. Decreased B cell proliferation upon MPA and 6-MP stimulation. A. A representative gating example of proliferating B cells. Within
CD19+CD22+ B cells, B cell proliferation was determined using histograms. Gates were set on the unstimulated sample. B. B cell proliferation is given for
both HCs and GPA patients for the unstimulated (US; squares), and CpG- (open triangles), MPA+CpG-(open diamonds), and 6-MP+CpG (open circles)
stimulated samples. C. B cell proliferation is depicted for unstimulated (US) PBMCs (squares), HCs (open triangle), MMF-treated (open diamonds) and
AZA-treated patients (open circles). Red lines represent the median value. �p<0.5, ��p<0.01, ���p<0.001.
https://doi.org/10.1371/journal.pone.0235743.g002
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Cy5 (BioLegend), and CD3-BV786. Afterwards, cells were treated with the Fix&Perm kit (Invi-
trogen, Life Technologies, Grand Island, NY, USA) and incubated with anti-human IL-10-PE,
and IL-6-APC and tumor necrosis factor (TNF)-α-AF488 (BioLegend) to stain intracellular
cytokines. Samples were acquired on a FACS LSRII and analyzed in Kaluza v1.5a. Gates were
set per donor on unstimulated sample. A representative gating example is given in Fig 2A.
To assess the influence of AZA and MMF on in vitro B cell cytokine production, PBMCs
were cultured at a concentration of 1�106 cells/mL in the presence of 500 ng/mL CpG or left
unstimulated. The same procedures and materials were used for restimulation and staining as
described above, except for two monoclonal antibodies: CD22-APC and IL-6-PE-Cy7
(eBioscience). Gates were set per donor on unstimulated sample. Representative gating exam-
ples are given in S2 Fig and Fig 3A.
Statistical analysis
Statistical analysis was performed using Graphpad Prism v7 (GraphPad Software, San Diego, CA,
USA). Data are presented as scatter dot plots with median values. Data within the text are repre-
sented as median values and range. Normality was tested using the Shapiro-Wilk test. If groups
were normally distributed, an unpaired T-test was performed to compare two groups. If all groups
were not normally distributed, the Mann-Whitney test was used to compare two groups. The Krus-
kal-Wallis (KW) test was used to test for differences between three or more groups for unpaired
samples, and the Dunn’s multiple comparisons test as a post-test to compare individual groups. A
Friedman test was used for paired samples, and the Dunn’s multiple comparisons post-test was
used to compare individual groups. P-values of<0.05 were considered statistically significant.
Fig 3. MPA decreases B cell IL-6 production. A. Representative gating example of B cell cytokine production. All
gates were set on the unstimulated sample for each donor. Within CD19+CD22+ B cells, IL-10+, IL-6+ and TNFα+ B
cells were determined. B. The frequencies of all cytokine-positive B cells are depicted for HCs (grey) and GPA patients
(black) in CpG only (open triangles), CpG+MPA (open diamonds), and CpG+6-MP (open circles) stimulated PBMCs.
C. IL-10+, IL-6+ and TNFα+ B cell frequencies in HCs (open triangles), MMF-treated (open diamonds) and AZA-
treated (open circles) GPA patients. Red lines represent the median value. �p<0.05, ��p<0.01, ���p<0.001.
https://doi.org/10.1371/journal.pone.0235743.g003
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Results
No difference in relapse-free survival between mycophenolate mofetil and
azathioprine-treated patients
We first compared relapse-free survival between untreated, MMF- and AZA-treated GPA
patients. Although both treated patient groups tended to have a reduced relapse-free survival,
there was no difference between MMF- and AZA-treated patients (S1B Fig).
Azathioprine treated GPA patients show an increased frequency of
circulating memory B cells
We then determined the frequencies of circulating B cell subsets in HCs and GPA patients that
were actively treated with MMF or AZA, and patients not receiving maintenance therapy
(untreated and treated patient cohorts 1; Fig 1A). The total B cell frequency was not signifi-
cantly different between MMF- and AZA-treated patients (Fig 1B). Only the memory B cell
population was significantly different between both treated patient groups: AZA-treated
patients presented with an increased memory B cell frequency (p = 0.0271; Fig 1B).
In line with previously published research [11], untreated GPA patients showed an
increased frequency of naïve B cells (p = 0.0016), whereas the memory B cell frequency was
decreased compared with HCs (p = 0.0001; S2A Fig). Untreated patients tended to have an
increased frequency of transitional B cells (p = 0.0769), whereas their CD24hiCD38hi Breg fre-
quency tended to be decreased compared with HCs (p = 0.0886; S2A Fig).
We also compared the absolute numbers of circulating lymphocytes and B cells between the
treated patient groups. No lymphocyte counts were available for the HCs. In the MMF-treated
patients the lymphocyte counts were reduced compared with untreated GPA patients
(p = 0.0061; S2B Fig). The B cell counts did not different between untreated patients and
MMF- and AZA-treated patients (S2B Fig).
Mycophenolic acid and 6-mercaptopurine inhibit B cell proliferation in
vitro
To assess the in vitro effect of MPA and 6-MP on B cell proliferation, we cultured CpG-stimu-
lated PBMCs of untreated GPA patients (Untreated cohort 3) and HCs in the presence or
absence of these compounds (Fig 2A). Both MPA and 6-MP inhibited B cell proliferation in
CpG-stimulated PBMCs from HCs compared to PBMCs stimulated with CpG only (Fig 2B).
In GPA patients MPA inhibited B cell proliferation in GPA patients, whereas 6-MP tended to
do so (Fig 2B).
Subsequently, we determined whether in patients treated with MMF or AZA the capacity of
B cells to proliferate differed (Treated cohort 4). As shown in Fig 2C, CpG stimulation of
PBMCs from MMF- and AZA-treated patients induced in vitro B cell proliferation compared
to the unstimulated samples. However, the frequencies of proliferating B cells of MMF- and
AZA-treated patients were similar to those observed in CpG-stimulated PBMCs from HCs.
Mycophenolic acid decreases the frequency of IL-6+ B cells in vitro
Finally, we determined the effect of MPA and 6-MP on B cell cytokine production in vitro in
untreated cohort 2. In PBMC cultures of GPA patients and HCs, MPA significantly decreased
IL-6+ B cell frequencies compared to samples treated with 6-MP, but did not affect the fre-
quencies of TNFα+ B cells compared to (Fig 3B). Interestingly, MPA reduced the proportion
of IL-10+ B cells compared to CpG stimulation in PBMC cultures of HCs but not of GPA
PLOS ONE Effects of AZA and MMF on B cell proliferation and cytokine production in GPA
PLOS ONE | https://doi.org/10.1371/journal.pone.0235743 July 9, 2020 7 / 12
patients (Fig 3B). Addition of 6-MP to the PBMC cultures did not affect the IL-10+, IL-6+ and
TNFα+ B cell frequencies in GPA patients.
We next assessed the capacity of B cells from MMF- and AZA-treated GPA patients to pro-
duce cytokines (Treated cohort 3). As shown in Fig 3C, CpG-stimulated PBMCs from MMF-
or AZA-treated patients showed similar IL-10+, IL-6+ or TNFα+ B cell frequencies compared
to CpG-stimulated PBMCs from HCs (Fig 3C).
Discussion
MMF and AZA are drugs that are commonly used to suppress the immune systems of patients
with autoimmune diseases. These drugs are effective in maintaining disease remission in GPA
patients [14]. Importantly, clinical data indicate that GPA patients treated with MMF are more
prone to disease relapses [14,16]. Here, we hypothesized that the previously observed differ-
ence in relapse rates between MMF- and AZA-treated GPA patients may be due to drug-
related differential effects on B cell subset frequencies and/or functioning. To this end, we
assessed whether immunomodulation by MMF and AZA altered B cell subset distribution,
and whether the active compounds of these drugs differentially affected B cell functions in
GPA patients and HCs.
The increased naïve B cell and decreased memory B cell frequencies in GPA patients com-
pared with HCs is in line with previously published results [11]. Comparing MMF- to AZA-
treated patients revealed that the memory B cell frequency was increased in AZA-treated
patients, whereas none of the other subsets were different. We subsequently studied B cell pro-
liferation and showed that MPA inhibited in vitro B cell proliferation in HCs and GPA
patients, while 6-MP only inhibited B cell proliferation in HCs. Moreover, MPA reduced the
in vitro IL-6+ B cell frequency in HCs and GPA patients whereas 6-MP did not. Next, we
aimed to confirm these in vitro effects on B cell cytokine production by assessing B cell cyto-
kine production and proliferation in PBMC samples from GPA patients receiving MMF or
AZA treatment. However, no differential effect on B cell proliferation or cytokine profile was
detected between MMF- and AZA-treated patients.
MMF and AZA are known to affect B cell frequencies in the circulation of patients suffering
from autoimmune diseases. Eickenberg et al. found a decreased transitional B cell frequency in
SLE patients treated with AZA compared with MMF-treated SLE patients [18]. We did not
find this difference in transitional B cell frequencies in GPA patients. However, in line with
our observations, these authors also reported increased circulating memory B cell frequencies
in AZA- compared to MMF-treated SLE patients. Eickenberg et al. argued that MMF, in con-
trast to AZA, spared naïve B cells of SLE patients whereas it profoundly decreased antigen-
experienced B cells and their functioning (i.e. antibody production and proliferation) [18].
Although we did not assess antibody production, this differential effect of MMF on antigen-
experienced B cells might also be responsible for the decreased memory B cell frequencies in
MMF-treated GPA patients observed in our study. However, it is unknown whether these dif-
ferential effects occur due to direct effects of the drugs on B cells or indirectly due to inhibition
of innate immune cells or T cells.
An important feature of MMF and AZA is the inhibition of immune cell proliferation.
Unexpectedly, we did not observe decreased B cell proliferation in cultured PBMC samples
from MMF- and AZA-treated GPA patients (compared with HC) upon CpG stimulation. Pre-
vious studies have shown that the active compound of MMF, MPA, is capable of inhibiting T-
[4] and B cell proliferation [19] in vitro in HCs. MPA was also capable of halting T- and B cell
proliferation in patients with active autoimmune hepatitis [25] and SLE [18], respectively. In
contrast, 6-MP only inhibited T cell proliferation at high concentrations (>10 nM) [4] or not
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at all [25]. Here, we show that MPA and 6-MP are both capable of inhibiting B cell prolifera-
tion in HCs at a concentration of 3 μM. However, we did not observe differences in the prolif-
erative capacity of B cells from MMF- or AZA- treated patients. It is unclear why these
differences were not observed; however, one could speculate that in vitro concentrations of the
active drug compounds differ from concentrations that are reached in the circulation. In this
context, a study in autoimmune hepatitis patients reported blood MPA concentrations of up
to 1–3.5 μg/L [25]. In our in vitro studies, we used 1 μg/L (= 3 μM) MPA indicating that the
applied in vitro concentrations are in the range of circulating concentrations reached when
patients receive MMF treatment. To date, no data are available for the 6-MP concentrations in
the circulation.
We also investigated the effects of both drugs and their active compounds on B cell function
by assessing their capacity to secrete cytokines upon CpG stimulation. IL-6 and TNFα produc-
tion by B cells is considered to promote the inflammatory response. We showed that neither
MPA nor 6-MP affected the TNFα+ B cell frequencies. This is in contrast to others who did
show that MPA decreased TNFα production in B cell cultures of HCs [26]. A possible explana-
tion for this discrepancy might be a different set-up of the in vitro cultures. Wadia et al. cul-
tured B cells in the presence of a stimulation cocktail [26], while we cultured PBMCs and
stimulated B cells with CpG. Interestingly, we found that MPA decreased IL-6+ B cell frequen-
cies in both GPA patients and HCs, whereas these frequencies were not different in 6-MP
treated samples.
The current exploratory study has several limitations. First, only small groups of patients
and HCs were included, therefore, our study can be underpowered to detect differences
between MMF and AZA. The limited patients included might also explain the lack of differ-
ence in relapse-free survival between MMF- and AZA-treated patients in our study. Hence,
our findings should be interpreted with caution and preferably be validated in larger patient
cohorts. Second, we did not consider differences in induction therapy, which mainly consisted
of cyclophosphamide, and its profound effect on the immune system, although included GPA
patients were in stable remission for at least 6 months. Third, the in vitro concentrations of the
active drug compounds, as discussed above, potentially differ from the concentrations that are
reached in the circulation. In addition, intracellular cytokine production was measured, and
synthesis not necessarily equates secretion. Lastly, we did not assess the effects of both immu-
nosuppressive drugs on serum immunoglobulin or ANCA levels. These could be interesting
indicators to link the effect of MMF and AZA on B cell functioning with their differential effect
on relapse rate.
In conclusion, we showed that MPA—the active compound of MMF—inhibits, in contrast
to 6-MP, in vitro pro-inflammatory B cell cytokine production in GPA patients and HCs,
while both compounds inhibited B cell proliferation. MMF could be, at least in vitro, more
effective in inhibiting the pro-inflammatory B cell response of GPA patients compared to
AZA. More research is needed to assess the effects of both immunosuppressive drugs on other
(pathogenic) immune cells in GPA, to elucidate the immune mechanisms underlying the dif-
ference in relapse rates between MMF- and AZA-treated patients and to identify the most
effective target for therapy.
Supporting information
S1 Fig. Representative gating strategy for the identification of B cells. A. Gates were set on
lymphocytes using the FSC-A/SSC-A plot. Within the lymphocytes, CD19+ B cells were gates.
Within the B cell population, subsets were gated as shown in Fig 1A. B. Relapse-free survival
in a Kaplan-Meier curve shown for untreated (triangles), and AZA- (circles), and MMF-
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treated (lines) patients over time (months).
(TIF)
S2 Fig. B cell subset distribution in HCs and untreated GPA patients. A. The frequencies of
B cells and B cell subsets in HCs (pyramids) and untreated GPA patients (circles). B. The lym-
phocyte and B cell counts (x106/L) in untreated GPA patients, MMF- and AZA-treated
patients. Red lines represent the median value. ��p<0.01, ���p<0.001, ����p<0.0001, #p<0.1
(TIF)
S3 Fig. Representative gating strategy used to assess B cell proliferation and cytokine pro-
duction. Using the FSC-A/SSC-A plot, lymphocytes were gated. Within the lymphocytes, dou-
blets were excluded using the FSC-A/FSC-H plot. Next, live cells were gated using the live/
dead/SSC-A plot. Within the live cells, CD3- cells were selected. The CD3- cell population was
used to gate on CD19+CD22+ B cells using the CD19/CD22 plot. Representative gating exam-
ples of proliferating and cytokine positive B cells are given in Figs 2A and 3A, respectively.
(TIF)
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